GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » Dividend Yield %

Lirum Therapeutics (Lirum Therapeutics) Dividend Yield % : 0.00% (As of Jun. 11, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Lirum Therapeutics Dividend Yield %?

As of today (2024-06-11), the Trailing Annual Dividend Yield of Lirum Therapeutics is 0.00%.

The historical rank and industry rank for Lirum Therapeutics's Dividend Yield % or its related term are showing as below:

LRTX's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.65
* Ranked among companies with meaningful Dividend Yield % only.

Lirum Therapeutics's Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00.

As of today (2024-06-11), the Forward Dividend Yield % of Lirum Therapeutics is 0.00%.

Lirum Therapeutics's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Lirum Therapeutics Dividend Yield % Historical Data

The historical data trend for Lirum Therapeutics's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lirum Therapeutics Dividend Yield % Chart

Lirum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Dividend Yield %
- - -

Lirum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Sep23 Dec23
Dividend Yield % - - - - -

Competitive Comparison of Lirum Therapeutics's Dividend Yield %

For the Biotechnology subindustry, Lirum Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lirum Therapeutics's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lirum Therapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Lirum Therapeutics's Dividend Yield % falls into.



Lirum Therapeutics Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Lirum Therapeutics  (NAS:LRTX) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Lirum Therapeutics Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Lirum Therapeutics's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lirum Therapeutics (Lirum Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
590 Madison Avenue, 21st Floor, New York, NY, USA, 10022
Lirum Therapeutics Inc is clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Its product candidate, LX-101, formerly 765IGF-MTX, is a novel, clinical-stage, "next generation," precision-engineered targeted therapy directed to the IGF-1R.

Lirum Therapeutics (Lirum Therapeutics) Headlines

No Headlines